Manuel Monreal/X
Aug 31, 2025, 07:05
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal, coordinator of the RIETE registry, posted on X:
”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers
No major differences in GU or CI cancers
Should all cancer patients with acute VTE receive the same treatment strategy?”
Find it here.
Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis
Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal
Stay updated with Hemostasis Today.
Aurora Villalobos
Behnood Bikdeli
Bleeding Risk
cancer
Cihan Ay
David Jimenez
Hematology
Hemostasis Today
Javier Pagán-Escribano
Javier Trujillo-Santos
Luciano López-Jiménez
Manuel Monreal
Maurizio Ciammaichella
Montserrat Pérez-Pinar
PE
Pulmonary embolism
RIETE registry
venous thromboembolism (VTE)
-
Nov 2, 2026, 12:38Maria Τektonidou: Machine Learning – A New Approach to CVD Risk in SLE
-
Nov 2, 2026, 12:31Toby Richards: Screening for Iron Deficiency – Nearly 1 in 4 Women Anaemic
-
Nov 2, 2026, 12:22James P. Crowley: A New Adult Progenitor with Erythro-Myeloid Potential
-
Nov 2, 2026, 12:17Mokhtar Tazik: Plasma Self-Sufficiency and Sustainable Access
-
Nov 2, 2026, 12:09Alejandro González Veliz: Does More Calcium Mean More Stability
-
Nov 2, 2026, 12:05Zeev Dvashi: Advancing Synthetic Blood Technologies for Battlefield Medicine
-
Nov 2, 2026, 11:56Rob Maloney: Strengthening Patient Advocacy in Bleeding Disorders
-
Nov 2, 2026, 11:46William McKeown: Advancing Gene and Cell Therapies for Inherited Bleeding Disorders
-
Nov 2, 2026, 11:41Anawat Ratchatorn: Identifying Stroke Mimics in the Emergency Department